Skip to main content
Sign in Create a free account
Varsity Tutors
Sign in

Parenteral Medications - NAPLEX

  1. A 58-year-old man (weight 90 kg) is in the ICU with diabetic ketoacidosis (DKA) and is receiving an insulin infusion. Current medications: regular insulin IV infusion per protocol, 0.9% sodium chloride infusion, potassium chloride supplementation as needed. Allergies: none. Labs: glucose 620 mg/dL, anion gap 28, potassium 3.2 mEq/L (low), bicarbonate 12 mEq/L, SCr 1.1 mg/dL. The nurse asks whether to start the insulin infusion now. What is the most important consideration for this IV therapy?
    Answer: Hold insulin infusion and replete potassium first until potassium is at least 3.3 mEq/L This question tests the concept of safe insulin administration in diabetic ketoacidosis (DKA) with electrolyte considerations. The key patient-specific factor is the patient's hypokalemia (3.2 mEq/L), which can worsen with insulin therapy due to intracellular shifts. Option B is the best choice because holding insulin until potassium is at least 3.3 mEq/L prevents life-threatening hypokalemia and arrhythmias. Option A is incorrect as starting insulin without repletion risks cardiac complications; option C is suboptimal as IV insulin is standard for DKA; option D is inappropriate as bicarbonate is reserved for severe acidosis (pH <6.9). In DKA management, replete electrolytes before insulin to avoid shifts. A clinical pearl is to monitor potassium hourly during initial therapy.
  2. A 72-year-old woman (weight 60 kg) is admitted with urosepsis and is started on gentamicin IV in addition to ceftriaxone. Past medical history includes chronic kidney disease stage 3; allergies: none. Current medications: metoprolol succinate 50 mg PO daily. Labs: serum creatinine 1.4 mg/dL, potassium 4.0 mEq/L, AST/ALT within normal limits; estimated creatinine clearance is 35 mL/min. The provider orders gentamicin 7 mg/kg IV every 24 hours using actual body weight. What is the most important consideration for this IV therapy?
    Answer: Use extended-interval gentamicin with a post-dose level strategy and adjust interval based on renal function This question tests understanding of aminoglycoside dosing strategies in renal impairment. The patient has a CrCl of 35 mL/min, which still allows for extended-interval dosing of gentamicin with appropriate monitoring. Extended-interval dosing (7 mg/kg every 24-48 hours based on renal function) provides high peak concentrations for bacterial killing while allowing a drug-free interval to minimize toxicity. A random level drawn 6-14 hours after the dose helps determine the appropriate interval. Continuous infusion (option B) is not standard practice and doesn't improve outcomes. Traditional dosing of every 8 hours (option C) increases toxicity risk without improving efficacy. Avoiding monitoring (option D) is dangerous, especially with renal impairment. The key principle is that extended-interval aminoglycoside dosing with appropriate monitoring optimizes efficacy while minimizing nephrotoxicity and ototoxicity.
  3. A 63-year-old man (weight 75 kg) is being treated for acute decompensated heart failure and is receiving multiple IV medications through a single peripheral IV line. Past medical history includes heart failure with reduced ejection fraction and atrial fibrillation; allergies: none. Current medications/orders: furosemide 40 mg IV twice daily, amiodarone infusion, and a heparin infusion for anticoagulation. Labs: serum creatinine 1.1 mg/dL, potassium 3.8 mEq/L, magnesium 1.9 mg/dL, INR 1.1, AST/ALT within normal limits. The nurse asks to Y-site piggyback furosemide into the amiodarone line to save IV access. Which action should the pharmacist take to ensure safety?
    Answer: Recommend a separate IV line (or dedicated lumen) for amiodarone and avoid Y-site co-infusion with furosemide due to incompatibility risk This question evaluates knowledge of IV drug compatibility and safe administration practices. Amiodarone and furosemide are incompatible when co-infused through the same line due to precipitation risk, which could cause catheter occlusion or embolism. The safest approach is to use a separate IV line or dedicated lumen for amiodarone to avoid any compatibility issues. Simply having clear solutions (option B) doesn't guarantee compatibility. Mixing drugs directly in the same bag (option C) is dangerous and could cause immediate precipitation. IV push amiodarone (option D) is only used in cardiac arrest situations and doesn't solve the compatibility issue. The clinical principle is that IV drug compatibility must be verified before Y-site administration, and when in doubt, separate lines should be used to ensure patient safety.
  4. A 44-year-old woman (weight 65 kg) is receiving IV potassium chloride replacement for hypokalemia on a telemetry unit. Current medications: furosemide 20 mg IV twice daily, magnesium sulfate IV as needed. Allergies: none. Labs: potassium 2.7 mEq/L (low), magnesium 1.5 mg/dL (low), SCr 0.8 mg/dL. The nurse asks about safe administration parameters. Which action should the pharmacist take to ensure safety?
    Answer: Recommend concurrent magnesium repletion and appropriate infusion rates/line type for potassium chloride This question tests the concept of safe IV electrolyte repletion in hypokalemia and hypomagnesemia. The key patient-specific factor is the concurrent low magnesium, which impairs potassium repletion, and telemetry monitoring for safety. Option B is the best choice because repleting magnesium facilitates potassium correction, and using appropriate rates (e.g., 10 mEq/h central) prevents arrhythmias. Option A is incorrect as IV push potassium is dangerous; option C is suboptimal as potassium can be replaced concurrently; option D is inappropriate as dextrose may worsen hypokalemia. Replete magnesium first or concurrently in refractory hypokalemia. A clinical pearl is to use central lines for rates >10 mEq/h potassium to avoid irritation.
  5. A 54-year-old woman (weight 68 kg) with breast cancer is scheduled to receive paclitaxel IV infusion today. Past medical history includes asthma and prior infusion reaction to an unknown medication; allergies: none documented. Current medications: albuterol inhaler as needed, sertraline 50 mg PO daily. Labs: absolute neutrophil count 2,100/mm3^3, platelets 210,000/mm3^3, serum creatinine 0.8 mg/dL, AST/ALT within normal limits. The paclitaxel order is verified. What is the most important consideration for this IV therapy?
    Answer: Ensure appropriate premedication (e.g., corticosteroid, H1 blocker, and H2 blocker) is ordered to reduce hypersensitivity reactions This question tests knowledge of chemotherapy premedication protocols to prevent hypersensitivity reactions. Paclitaxel is formulated with Cremophor EL, which frequently causes hypersensitivity reactions including anaphylaxis. Standard premedication includes a corticosteroid (dexamethasone), H1 blocker (diphenhydramine), and H2 blocker (famotidine or ranitidine) given before infusion to significantly reduce reaction risk. Leucovorin rescue (option B) is used with methotrexate, not paclitaxel. Avoiding premedication (option C) would be dangerous given the high reaction risk. IV push administration (option D) would increase reaction risk and is never appropriate for paclitaxel. The key principle is that taxane chemotherapy requires specific premedication protocols to prevent potentially life-threatening hypersensitivity reactions, especially in patients with a history of drug reactions.
  6. A 47-year-old man (weight 92 kg, height 180 cm) is hospitalized with acute pancreatitis and is unable to tolerate enteral nutrition; the team plans to start total parenteral nutrition (TPN) via a PICC line. Current medications: hydromorphone IV as needed, ondansetron 4 mg IV every 6 hours as needed, enoxaparin 40 mg subcutaneously daily. Allergies: none. Labs: SCr 1.0 mg/dL, sodium 132 mEq/L (low), potassium 3.1 mEq/L (low), magnesium 1.4 mg/dL (low), phosphate 2.0 mg/dL (low), glucose 168 mg/dL, AST/ALT 40/45 units/L, triglycerides 380 mg/dL (high). What is the most important consideration for this IV therapy?
    Answer: Hold IV lipid emulsion initially and replete electrolytes aggressively due to refeeding risk and hypertriglyceridemia This question tests the concept of safe initiation of total parenteral nutrition (TPN) in patients at risk for refeeding syndrome. The key patient-specific factor is the patient's electrolyte imbalances, hypertriglyceridemia, and risk for refeeding due to acute pancreatitis and malnutrition. Option B is the best choice because holding lipids initially prevents worsening hypertriglyceridemia, and aggressive electrolyte repletion mitigates refeeding syndrome risks like hypophosphatemia. Option A is incorrect as delaying repletion increases arrhythmia risk; option C is suboptimal as adding insulin to TPN is not standard without hyperglycemia control protocols; option D is inappropriate as peripheral nutrition cannot meet full caloric needs without risking phlebitis. For TPN initiation, assess refeeding risk factors like low electrolytes and start conservatively with monitoring. A clinical pearl is to replete phosphate, potassium, and magnesium before or during TPN to prevent severe complications.
  7. A 61-year-old man (weight 88 kg) is admitted for acute bacterial meningitis and is started on meropenem IV. Current medications: none. Allergies: none. Labs: SCr 3.0 mg/dL, BUN 60 mg/dL, sodium 140 mEq/L, potassium 4.8 mEq/L, AST/ALT 25/20 units/L. The initial order is meropenem 2 g IV every 8 hours. What dose adjustment is needed for this patient's renal function?
    Answer: Reduce meropenem dose/frequency based on creatinine clearance and reassess as renal function changes This question tests the concept of renal dose adjustment for carbapenems in severe infections. The key patient-specific factor is the patient's acute kidney injury with SCr 3.0 mg/dL, reducing meropenem clearance. Option B is the best choice because adjusting meropenem dose/frequency (e.g., 1 g q12h for CrCl <30 mL/min) prevents accumulation and seizures while maintaining efficacy. Option A is incorrect as no adjustment risks neurotoxicity; option C is suboptimal as increasing dose worsens accumulation; option D is inappropriate as oral meropenem does not exist. Calculate CrCl and adjust per package insert for renally cleared antibiotics. A decision framework is to reassess renal function daily in critically ill patients for dynamic dosing.
  8. A 45-year-old man (weight 90 kg, height 178 cm) with Crohn disease has been unable to tolerate enteral nutrition for 7 days due to high-output ileostomy and is started on total parenteral nutrition (TPN) via a double-lumen PICC. Past medical history includes malnutrition; allergies: none. Current medications: pantoprazole 40 mg IV daily, hydromorphone PCA. Labs: sodium 138 mEq/L, potassium 3.1 mEq/L (low), magnesium 1.4 mg/dL (low), phosphate 2.2 mg/dL (low), serum creatinine 0.9 mg/dL, AST/ALT within normal limits, glucose 168 mg/dL. The TPN order is being finalized. Which action should the pharmacist take to ensure safety?
    Answer: Increase potassium, magnesium, and phosphate in the TPN and recommend thiamine supplementation due to refeeding risk This question addresses refeeding syndrome prevention in a malnourished patient starting TPN. The patient has multiple electrolyte deficiencies (low potassium, magnesium, and phosphate) and has been NPO for 7 days, placing him at high risk for refeeding syndrome. The correct approach is to replete electrolytes in the TPN and supplement thiamine before aggressive nutrition support to prevent cardiac and neurologic complications. Holding all electrolytes (option B) would worsen deficiencies and increase refeeding risk. Adding calcium chloride and phosphate together (option C) would cause precipitation and is incompatible. Starting maximum lipids while omitting dextrose (option D) doesn't address the electrolyte issues and could worsen the metabolic state. The clinical pearl is that malnourished patients require electrolyte repletion and thiamine supplementation before initiating aggressive nutrition support to prevent potentially fatal refeeding syndrome.
  9. A 69-year-old man (weight 86 kg) with atrial fibrillation on chronic warfarin presents with intracranial hemorrhage and needs urgent reversal. Current medications: warfarin 5 mg by mouth daily, amiodarone 200 mg by mouth daily. Allergies: none. Labs: INR 4.2 (high), hemoglobin 13.2 g/dL, platelets 210 x103x10^3/mcL, SCr 1.0 mg/dL. Which parenteral medication is most appropriate for this patient?
    Answer: Vitamin K 10 mg IV plus 4-factor prothrombin complex concentrate (PCC) dosed by INR and weight This question tests the concept of urgent reversal of warfarin in major bleeding. The key patient-specific factor is the intracranial hemorrhage and elevated INR of 4.2, requiring rapid correction. Option A is the best choice because 4-factor PCC provides immediate reversal, and vitamin K ensures sustained effect. Option B is incorrect as FFP is slower and less effective without vitamin K; option C is suboptimal as protamine reverses heparin, not warfarin; option D is inappropriate as idarucizumab reverses dabigatran. Use PCC for life-threatening warfarin bleeds per guidelines. A clinical pearl is to dose PCC by INR and weight for optimal efficacy.
  10. A 46-year-old man (weight 95 kg) is admitted with severe alcohol withdrawal and is on a symptom-triggered benzodiazepine protocol. Current medications: lorazepam IV as needed per protocol, thiamine 100 mg IV daily, folic acid 1 mg by mouth daily. Allergies: none. Labs: AST/ALT 110/85 units/L (elevated), total bilirubin 1.2 mg/dL, INR 1.3, SCr 0.9 mg/dL. The team asks which IV benzodiazepine is preferred if continuous infusion is required. Which parenteral medication is most appropriate for this patient?
    Answer: Lorazepam IV (intermittent or infusion) because it is less dependent on hepatic oxidation This question tests the concept of benzodiazepine selection in alcohol withdrawal with hepatic impairment. The key patient-specific factor is the patient's elevated liver enzymes, affecting metabolism of certain benzodiazepines. Option B is the best choice because lorazepam undergoes glucuronidation, which is less impaired in liver disease, making it safer for intermittent or continuous use. Option A is incorrect as diazepam has prolonged half-life in cirrhosis; option C is suboptimal as midazolam is hepatically oxidized; option D is inappropriate as chlordiazepoxide is oral and hepatically metabolized. Prefer lorazepam or oxazepam in hepatic dysfunction for withdrawal. A clinical pearl is to use CIWA-Ar scores to guide symptom-triggered dosing.
  11. A 71-year-old woman (weight 59 kg) is admitted with acute kidney injury and hyperkalemia with ECG changes (peaked T waves). Current medications: lisinopril 20 mg by mouth daily, spironolactone 25 mg by mouth daily. Allergies: none. Labs: potassium 6.8 mEq/L (high), SCr 3.4 mg/dL, bicarbonate 18 mEq/L, glucose 160 mg/dL. The provider orders calcium gluconate IV, insulin with dextrose IV, and albuterol nebulization. Which monitoring parameter should be assessed during administration of insulin with dextrose?
    Answer: Blood glucose monitoring for hypoglycemia This question evaluates monitoring requirements for emergency treatment of hyperkalemia using parenteral medications. The key patient-specific factor is the administration of insulin with dextrose to shift potassium intracellularly, alongside the patient's baseline glucose of 160 mg/dL. Blood glucose monitoring for hypoglycemia is the best choice because insulin can rapidly lower blood sugar, potentially causing symptomatic hypoglycemia if not monitored closely. INR monitoring for bleeding is incorrect as there are no anticoagulants involved, and serum vancomycin trough is irrelevant since vancomycin is not being administered. Absolute neutrophil count is suboptimal as it does not relate to the acute effects of insulin-dextrose therapy. A transferable clinical pearl is that insulin-dextrose for hyperkalemia should include point-of-care glucose checks every 30-60 minutes for at least 4 hours post-administration. In decision-making, prioritize monitoring for the most immediate and predictable adverse effect of the intervention being used.
  12. A 66-year-old man (weight 78 kg) is admitted with acute upper gastrointestinal bleeding and hypotension; he is receiving IV fluids while awaiting endoscopy. Current medications: aspirin 81 mg by mouth daily (held), clopidogrel 75 mg by mouth daily (held), omeprazole 20 mg by mouth daily. Allergies: none. Labs: hemoglobin 6.8 g/dL (low), platelets 220 x103x10^3/mcL, INR 1.1, SCr 1.0 mg/dL, lactate 3.2 mmol/L (high). What is the most appropriate fluid resuscitation choice initially?
    Answer: 0.9% sodium chloride bolus while preparing for blood product transfusion This question tests the concept of fluid resuscitation in hemorrhagic shock to stabilize hemodynamics. The key patient-specific factor is the patient's hypotension, low hemoglobin, and elevated lactate, indicating hypovolemic shock from GI bleeding. Option A is the best choice because 0.9% sodium chloride bolus provides isotonic volume expansion while preparing for blood transfusion, which is definitive therapy. Option B is incorrect as dextrose causes hyponatremia without sustained volume; option C is suboptimal as hypotonic fluids worsen hyponatremia; option D is inappropriate as hypertonic saline risks fluid overload. For hypovolemic shock, use crystalloids initially followed by blood products. A decision framework is to assess lactate and hemoglobin to guide resuscitation endpoints.
  13. A 61-year-old man (weight 100 kg) is admitted for intra-abdominal infection and is started on piperacillin-tazobactam IV. Past medical history includes type 2 diabetes and chronic kidney disease; allergies: none. Current medications: insulin lispro with meals, atorvastatin 40 mg PO nightly. Labs: serum creatinine 3.0 mg/dL, potassium 4.3 mEq/L, AST/ALT within normal limits; estimated creatinine clearance is 18 mL/min. The provider orders piperacillin-tazobactam 3.375 g IV every 6 hours (30-minute infusion). What dose adjustment is needed for this patient's renal function?
    Answer: Change to piperacillin-tazobactam 2.25 g IV every 8 hours This question evaluates piperacillin-tazobactam dosing in severe renal impairment. The patient has a CrCl of 18 mL/min, which requires significant dose adjustment to prevent accumulation of both piperacillin and tazobactam. For CrCl <20 mL/min, the recommended dose is 2.25 g every 8 hours (or every 6 hours for Pseudomonas). Option A (no adjustment) would lead to significant drug accumulation and increased risk of neurotoxicity including seizures. Option B reduces frequency but maintains too high a dose. Option D increases the dose inappropriately. The key principle is that beta-lactam/beta-lactamase inhibitor combinations require both dose and interval adjustments in severe renal impairment, with more aggressive reductions needed when CrCl falls below 20 mL/min to prevent CNS toxicity.
  14. A 33-year-old woman (weight 54 kg) is admitted for severe migraine with persistent vomiting and cannot take oral medications. Current medications: sumatriptan 50 mg by mouth as needed (home), sertraline 100 mg by mouth daily (home). Allergies: metoclopramide (severe akathisia). Labs: SCr 0.8 mg/dL, AST/ALT 16/14 units/L, pregnancy test negative. The provider wants an IV option for acute migraine treatment. Which parenteral medication is most appropriate for this patient?
    Answer: Prochlorperazine 10 mg IV once with diphenhydramine 25 mg IV once This question tests the concept of IV abortive therapy for acute migraine in patients with contraindications. The key patient-specific factor is the patient's allergy to metoclopramide, necessitating an alternative antiemetic with diphenhydramine to prevent dystonia. Option A is the best choice because prochlorperazine with diphenhydramine effectively treats migraine without the akathisia risk of metoclopramide. Option B is incorrect due to the allergy; option C is suboptimal as opioids are not first-line; option D is inappropriate as ergotamine risks vasoconstriction. Use neuroleptics with anticholinergics for migraine when triptans fail. A decision framework is to assess allergies and use evidence-based IV options like prochlorperazine.
  15. A 59-year-old woman (weight 68 kg) with chronic kidney disease is started on IV acyclovir for suspected HSV encephalitis. Current medications: sertraline 50 mg by mouth daily, amlodipine 5 mg by mouth daily. Allergies: none. Labs: SCr 2.8 mg/dL, BUN 52 mg/dL, sodium 137 mEq/L, potassium 4.4 mEq/L. What is the most important consideration for this IV therapy?
    Answer: Ensure renal dose adjustment and adequate IV hydration to reduce risk of crystal nephropathy This question tests the concept of preventing nephrotoxicity with acyclovir in renal impairment. The key patient-specific factor is the patient's chronic kidney disease with SCr 2.8 mg/dL, increasing risk for crystal nephropathy. Option B is the best choice because dose adjustment (e.g., 10 mg/kg q24h) and hydration reduce crystal formation and maintain efficacy. Option A is incorrect as rapid push increases nephrotoxicity; option C is suboptimal as fluids are needed to prevent crystals; option D is inappropriate as topical acyclovir is ineffective for encephalitis. Adjust acyclovir dose by CrCl and infuse over 1 hour with hydration. A decision framework is to monitor urine output and SCr daily during therapy.
  16. A 50-year-old man (weight 100 kg, height 175 cm) is admitted with skin and soft tissue infection and is started on IV trimethoprim/sulfamethoxazole is not an option due to allergy; the team chooses IV linezolid. Current medications: paroxetine 40 mg by mouth daily, tramadol 50 mg by mouth every 6 hours as needed (home). Allergies: sulfonamides (hives). Labs: SCr 0.9 mg/dL, platelets 160 x103x10^3/mcL, AST/ALT 24/22 units/L. What is the most important consideration for this IV therapy?
    Answer: Assess for serotonin syndrome risk and consider holding or changing serotonergic agents while on linezolid This question tests the concept of drug interactions with linezolid, particularly serotonergic effects. The key patient-specific factor is the patient's use of paroxetine and tramadol, increasing serotonin syndrome risk with linezolid. Option B is the best choice because assessing and mitigating serotonergic agents (e.g., holding paroxetine) prevents toxicity while allowing linezolid use. Option A is incorrect as linezolid inhibits MAO, causing interactions; option C is suboptimal as linezolid is not contraindicated in normal kidneys; option D is inappropriate as rifampin reduces linezolid levels. Screen for serotonergic drugs and monitor for syndrome symptoms. A decision framework is to weigh infection severity against interaction risks and consider alternatives like daptomycin.
  17. A 60-year-old man (weight 79 kg) is receiving IV cefepime for hospital-acquired pneumonia. Current medications: cefepime 2 g IV every 8 hours, albuterol inhaler as needed. Allergies: none. Labs: SCr 2.6 mg/dL, BUN 55 mg/dL, sodium 142 mEq/L, potassium 4.1 mEq/L. On day 3, the patient develops confusion and myoclonus. What is the most important consideration for this IV therapy?
    Answer: Assess for cefepime accumulation due to renal impairment and recommend renal dose adjustment or alternative therapy This question tests the recognition of antibiotic-induced neurotoxicity in the context of parenteral medications. The key patient-specific factor is the elevated serum creatinine (SCr 2.6 mg/dL) and BUN (55 mg/dL), indicating renal impairment that affects cefepime clearance. Assessing for cefepime accumulation due to renal impairment and recommending dose adjustment or alternative therapy is the best choice because cefepime is primarily renally excreted, and accumulation can lead to neurotoxic effects like confusion and myoclonus. Increasing the dose is incorrect as it would worsen potential accumulation and neurotoxicity without addressing the underlying renal issue, while adding diphenhydramine assumes an allergic reaction, which is unlikely given the symptoms and lack of allergy history. Switching to oral cefepime is suboptimal because oral formulations are not equivalent for severe infections like hospital-acquired pneumonia and do not inherently prevent neurotoxicity. A key clinical pearl is that beta-lactam antibiotics like cefepime require renal dose adjustments to prevent adverse effects in patients with impaired kidney function. Always calculate creatinine clearance using tools like Cockcroft-Gault to guide dosing decisions in such scenarios.
  18. A 72-year-old woman (weight 70 kg) presents with acute decompensated heart failure and pulmonary edema; she is dyspneic and requires IV diuresis. Current medications: furosemide 40 mg by mouth daily, metoprolol succinate 50 mg by mouth daily, spironolactone 25 mg by mouth daily. Allergies: sulfonamide antibiotics (rash). Labs: SCr 1.6 mg/dL, sodium 128 mEq/L (low), potassium 5.3 mEq/L (high), BNP 1,200 pg/mL. The provider orders IV furosemide. Which monitoring parameter should be assessed during administration?
    Answer: Serum potassium and daily weights/urine output This question tests the concept of monitoring for electrolyte imbalances and fluid status during IV diuretic therapy. The key patient-specific factor is the patient's hyperkalemia, hyponatremia, and renal impairment in the setting of heart failure exacerbation. Option A is the best choice because IV furosemide can cause hypokalemia and fluid shifts, necessitating close monitoring of potassium, weights, and urine output to guide therapy and prevent dehydration. Option B is incorrect as INR is not directly affected by furosemide; option C is suboptimal as neutropenia is not a common side effect; option D is inappropriate as amylase/lipase are unrelated to diuretic monitoring. In diuretic therapy, establish baseline electrolytes and monitor daily to adjust dosing. A decision framework is to balance diuresis with electrolyte replacement to avoid arrhythmias or worsening renal function.
  19. A 58-year-old woman (weight 70 kg) is hospitalized with MRSA bacteremia and is receiving vancomycin IV. Past medical history includes type 2 diabetes and chronic kidney disease; allergies: none. Current medications: insulin glargine 20 units SC nightly, lisinopril 10 mg PO daily. Labs: serum creatinine 1.9 mg/dL (baseline 1.2), potassium 5.1 mEq/L (high), AST/ALT within normal limits; estimated creatinine clearance is 35 mL/min. She is currently ordered vancomycin 1,250 mg IV every 12 hours. Which monitoring parameter should be assessed during administration to best ensure safe and effective therapy?
    Answer: Vancomycin area under the curve (AUC) or trough concentration, along with serum creatinine trending This question evaluates understanding of vancomycin therapeutic drug monitoring in the setting of renal dysfunction. The patient has worsening renal function (creatinine increased from 1.2 to 1.9 mg/dL) and is at high risk for vancomycin-induced nephrotoxicity. Current guidelines recommend AUC-based monitoring (target 400-600 mg·h/L) or trough monitoring (15-20 mcg/mL for serious infections) along with serum creatinine trending to detect nephrotoxicity early. INR monitoring (option B) is irrelevant as vancomycin doesn't affect coagulation. Amylase/lipase monitoring (option C) is unnecessary as vancomycin doesn't cause pancreatitis. While vancomycin can rarely prolong QTc (option D), this is not routine monitoring. The key principle is that vancomycin requires therapeutic drug monitoring to balance efficacy against nephrotoxicity, especially in patients with baseline renal impairment.
  20. A 52-year-old woman (weight 73 kg) is receiving ceftriaxone 2 g IV every 24 hours for pyelonephritis and now requires IV calcium gluconate for symptomatic hypocalcemia (perioral tingling, QT prolongation). Current medications: ceftriaxone 2 g IV daily, normal saline at keep vein open rate. Allergies: none. Labs: calcium 6.8 mg/dL (low), albumin 2.8 g/dL, magnesium 1.6 mg/dL (low), SCr 0.7 mg/dL. The nurse asks if calcium gluconate can be Y-sited with ceftriaxone. Which action should the pharmacist take to ensure safety?
    Answer: Avoid co-administration; use separate lines or thoroughly flush between ceftriaxone and calcium-containing solutions This question tests the concept of IV drug compatibility, specifically the ceftriaxone-calcium interaction. The key patient-specific factor is the patient's hypocalcemia requiring IV calcium gluconate while on ceftriaxone. Option B is the best choice because avoiding co-administration and flushing lines prevents precipitate formation, which can cause serious adverse events like embolization. Option A is incorrect as ceftriaxone is incompatible with calcium; option C is suboptimal without need, as ceftriaxone is appropriate; option D is dangerous as peripheral calcium chloride causes tissue necrosis. Always check for known incompatibilities like ceftriaxone-calcium in adults. A clinical pearl is to separate administration by at least 1 hour if using the same line.

Start this quiz